Global Monoclonal Antibody Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

Description

List of Tables

The global demand for Monoclonal Antibody Market is presumed to reach the market size of nearly USD 269.15 Billion by 2032 from USD 236.23 Billion in 2023 with a CAGR of 1.46% under the study period 2024-2032.

Monoclonal antibodies (mAb or moAb) are a protein type made in the laboratory that can bind to substances in the body. They are identical immunoglobulins generated from a single B-cell clone. Monoclonal antibodies are employed to treat many diseases and can be used alone or carry drugs, toxins, or radioactive substances. There are many varieties of monoclonal antibodies and different ways of making them, and they are named based on how they are made of chimeric, murine, humanized, and human. Monoclonal antibodies recognize unique epitopes, or binding sites, on a single antigen. They act like human antibodies in the immune system.

MARKET DYNAMICS

Monoclonal antibodies (mAb or moAb) have become an important tool in biochemistry, molecular biology, and medicine. Rising incidence of chronic diseases and cancer, increasing regulatory approvals, the launch of therapies, and growing R&D primarily drive the global monoclonal antibody market. Chronic diseases and cancer are the leading cause of death worldwide. According to the World Health Organization estimates, chronic diseases are responsible for around two-thirds of all deaths worldwide. In 2020, cancer caused the death of nearly 10 million people. Monoclonal antibodies have gained attention with the rise of the COVID-19 pandemic. They have progressed to allow more widespread use. Monoclonal antibodies offer many benefits to the pharmaceutical industry and treat the COVID-19 pandemic, including short production time, low cost, highly stable and tolerant of pH or buffer changes, high affinity, and tolerance of minor antigen changes. Monoclonal antibodies are identified as a promising approach for treating COVID-19 patients. Robust research is being carried out to use it to treat COVID-19. However, higher costs associated with a monoclonal antibody, strict regulatory measures, low awareness about monoclonal antibody, and lack of research is likely to hamper the market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Monoclonal Antibody. The growth and trends of Monoclonal Antibody industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Monoclonal Antibody market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Source

Murine
Chimeric
Humanized
Human

By Production

In Vivo
In Vitro

By Application

Oncology
Autoimmune Diseases
Infectious Diseases
Neurological Diseases
Others

By End-use

Hospitals
Specialty Centers
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Monoclonal Antibody market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Monoclonal Antibody market include Novartis AG, Pfizer Inc, GlaxoSmithKline Plc, Amgen Inc., Merck & Co. Inc., Daiichi Sankyo Company, Limited, Abbott Laboratories, AstraZeneca Plc, Eli Lilly And Company, Johnson & Johnson Services Inc., Bayer AG, Bristol Myers Squibb, F. Hoffman-La Roche Ltd., Viatris Inc., Biogen Inc., Thermo Fisher Scientific Inc., Novo Nordisk A/S, Sanofi S.A., Merck KGaA. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR11215463

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. MONOCLONAL ANTIBODY - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Source
- 3.7.2 Market Attractiveness Analysis By Production
- 3.7.3 Market Attractiveness Analysis By Application
- 3.7.4 Market Attractiveness Analysis By End-use
- 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL MONOCLONAL ANTIBODY MARKET ANALYSIS BY SOURCE

5.1. Overview By Source
5.2. Historical and Forecast Data Analysis By Source
5.3. Murine Historic and Forecast Sales By Regions
5.4. Chimeric Historic and Forecast Sales By Regions
5.5. Humanized Historic and Forecast Sales By Regions
5.6. Human Historic and Forecast Sales By Regions

6. GLOBAL MONOCLONAL ANTIBODY MARKET ANALYSIS BY PRODUCTION

6.1. Overview By Production
6.2. Historical and Forecast Data Analysis By Production
6.3. In Vivo Historic and Forecast Sales By Regions
6.4. In Vitro Historic and Forecast Sales By Regions

7. GLOBAL MONOCLONAL ANTIBODY MARKET ANALYSIS BY APPLICATION

7.1. Overview By Application
7.2. Historical and Forecast Data Analysis By Application
7.3. Oncology Historic and Forecast Sales By Regions
7.4. Autoimmune Diseases Historic and Forecast Sales By Regions
7.5. Infectious Diseases Historic and Forecast Sales By Regions
7.6. Neurological Diseases Historic and Forecast Sales By Regions
7.7. Others Historic and Forecast Sales By Regions

8. GLOBAL MONOCLONAL ANTIBODY MARKET ANALYSIS BY END-USE

8.1. Overview By End-use
8.2. Historical and Forecast Data Analysis By End-use
8.3. Hospitals Historic and Forecast Sales By Regions
8.4. Specialty Centers Historic and Forecast Sales By Regions
8.5. Others Historic and Forecast Sales By Regions

9. GLOBAL MONOCLONAL ANTIBODY MARKET ANALYSIS BY GEOGRAPHY

9.1. Regional Outlook
9.2. Introduction
9.3. North America Sales Analysis
- 9.3.1 Overview, Historic and Forecast Data Sales Analysis
- 9.3.2 North America By Segment Sales Analysis
- 9.3.3 North America By Country Sales Analysis
- 9.3.4 United States Sales Analysis
- 9.3.5 Canada Sales Analysis
- 9.3.6 Mexico Sales Analysis
9.4. Europe Sales Analysis
- 9.4.1 Overview, Historic and Forecast Data Sales Analysis
- 9.4.2 Europe By Segment Sales Analysis
- 9.4.3 Europe By Country Sales Analysis
- 9.4.4 United Kingdom Sales Analysis
- 9.4.5 France Sales Analysis
- 9.4.6 Germany Sales Analysis
- 9.4.7 Italy Sales Analysis
- 9.4.8 Russia Sales Analysis
- 9.4.9 Rest Of Europe Sales Analysis
9.5. Asia Pacific Sales Analysis
- 9.5.1 Overview, Historic and Forecast Data Sales Analysis
- 9.5.2 Asia Pacific By Segment Sales Analysis
- 9.5.3 Asia Pacific By Country Sales Analysis
- 9.5.4 China Sales Analysis
- 9.5.5 India Sales Analysis
- 9.5.6 Japan Sales Analysis
- 9.5.7 South Korea Sales Analysis
- 9.5.8 Australia Sales Analysis
- 9.5.9 South East Asia Sales Analysis
- 9.5.10 Rest Of Asia Pacific Sales Analysis
9.6. Latin America Sales Analysis
- 9.6.1 Overview, Historic and Forecast Data Sales Analysis
- 9.6.2 Latin America By Segment Sales Analysis
- 9.6.3 Latin America By Country Sales Analysis
- 9.6.4 Brazil Sales Analysis
- 9.6.5 Argentina Sales Analysis
- 9.6.6 Peru Sales Analysis
- 9.6.7 Chile Sales Analysis
- 9.6.8 Rest of Latin America Sales Analysis
9.7. Middle East & Africa Sales Analysis
- 9.7.1 Overview, Historic and Forecast Data Sales Analysis
- 9.7.2 Middle East & Africa By Segment Sales Analysis
- 9.7.3 Middle East & Africa By Country Sales Analysis
- 9.7.4 Saudi Arabia Sales Analysis
- 9.7.5 UAE Sales Analysis
- 9.7.6 Israel Sales Analysis
- 9.7.7 South Africa Sales Analysis
- 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE MONOCLONAL ANTIBODY COMPANIES

10.1. Monoclonal Antibody Market Competition
10.2. Partnership/Collaboration/Agreement
10.3. Merger And Acquisitions
10.4. New Product Launch
10.5. Other Developments

11. COMPANY PROFILES OF MONOCLONAL ANTIBODY INDUSTRY

11.1. Top Companies Market Share Analysis
11.2. Market Concentration Rate
11.3. Novartis AG
- 11.3.1 Company Overview
- 11.3.2 Company Revenue
- 11.3.3 Products
- 11.3.4 Recent Developments
11.4. Pfizer Inc
- 11.4.1 Company Overview
- 11.4.2 Company Revenue
- 11.4.3 Products
- 11.4.4 Recent Developments
11.5. GlaxoSmithKline Plc
- 11.5.1 Company Overview
- 11.5.2 Company Revenue
- 11.5.3 Products
- 11.5.4 Recent Developments
11.6. Amgen Inc.
- 11.6.1 Company Overview
- 11.6.2 Company Revenue
- 11.6.3 Products
- 11.6.4 Recent Developments
11.7. Merck & Co. Inc.
- 11.7.1 Company Overview
- 11.7.2 Company Revenue
- 11.7.3 Products
- 11.7.4 Recent Developments
11.8. Daiichi Sankyo Company
- 11.8.1 Company Overview
- 11.8.2 Company Revenue
- 11.8.3 Products
- 11.8.4 Recent Developments
11.9. Limited
- 11.9.1 Company Overview
- 11.9.2 Company Revenue
- 11.9.3 Products
- 11.9.4 Recent Developments
11.10. Abbott Laboratories
- 11.10.1 Company Overview
- 11.10.2 Company Revenue
- 11.10.3 Products
- 11.10.4 Recent Developments
11.11. AstraZeneca Plc
- 11.11.1 Company Overview
- 11.11.2 Company Revenue
- 11.11.3 Products
- 11.11.4 Recent Developments
11.12. Eli Lilly And Company
- 11.12.1 Company Overview
- 11.12.2 Company Revenue
- 11.12.3 Products
- 11.12.4 Recent Developments
11.13. Johnson & Johnson Services Inc.
- 11.13.1 Company Overview
- 11.13.2 Company Revenue
- 11.13.3 Products
- 11.13.4 Recent Developments
11.14. Bayer AG
- 11.14.1 Company Overview
- 11.14.2 Company Revenue
- 11.14.3 Products
- 11.14.4 Recent Developments
11.15. Bristol Myers Squibb
- 11.15.1 Company Overview
- 11.15.2 Company Revenue
- 11.15.3 Products
- 11.15.4 Recent Developments
11.16. F. Hoffman-La Roche Ltd.
- 11.16.1 Company Overview
- 11.16.2 Company Revenue
- 11.16.3 Products
- 11.16.4 Recent Developments
11.17. Viatris Inc.
- 11.17.1 Company Overview
- 11.17.2 Company Revenue
- 11.17.3 Products
- 11.17.4 Recent Developments
11.18. Biogen Inc.
- 11.18.1 Company Overview
- 11.18.2 Company Revenue
- 11.18.3 Products
- 11.18.4 Recent Developments
11.19. Thermo Fisher Scientific Inc.
- 11.19.1 Company Overview
- 11.19.2 Company Revenue
- 11.19.3 Products
- 11.19.4 Recent Developments
11.20. Novo Nordisk A/S
- 11.20.1 Company Overview
- 11.20.2 Company Revenue
- 11.20.3 Products
- 11.20.4 Recent Developments
11.21. Sanofi S.A.
- 11.21.1 Company Overview
- 11.21.2 Company Revenue
- 11.21.3 Products
- 11.21.4 Recent Developments
11.22. Merck KGaA
- 11.22.1 Company Overview
- 11.22.2 Company Revenue
- 11.22.3 Products
- 11.22.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies